Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Patient-derived organoids as a platform for modeling a patient's response to chemoradiotherapy in esophageal cancer.

Authors: Karakasheva, Tatiana A; Gabre, Joel T; Sachdeva, Uma M; Cruz-Acuña, Ricardo; Lin, Eric W; DeMarshall, Maureen; Falk, Gary W; Ginsberg, Gregory G; Yang, Zhaohai; Kim, Michele M; Diffenderfer, Eric S; Pitarresi, Jason R; Li, Jinyang; Muir, Amanda B; Hamilton, Kathryn E; Nakagawa, Hiroshi; Bass, Adam J; Rustgi, Anil K

Published In Sci Rep, (2021 10 29)

Abstract: 3D patient-derived organoids (PDOs) have been utilized to evaluate potential therapies for patients with different cancers. However, the use of PDOs created from treatment-naive patient biopsies for prediction of clinical outcomes in patients with esophageal cancer has not yet been reported. Herein we describe a pilot prospective observational study with the goal of determining whether esophageal cancer PDOs created from treatment naive patients can model or predict clinical outcomes. Endoscopic biopsies of treatment-naive patients at a single tertiary care center were used to generate esophageal cancer PDOs, which were treated with standard-of-care chemotherapy, gamma-irradiation, and newer non-standard approaches, such as proton beam therapy or two small molecule inhibitors. Clinical outcomes of patients following neoadjuvant treatment were compared to their in vitro PDO responses, demonstrating the PDO's ability to mirror clinical response, suggesting the value of PDOs in prediction of clinical response to new therapeutic approaches. Future prospective clinical trials should test the use of pre-treatment PDOs to identify specific, targeted therapies for individual patients with esophageal adenocarcinoma.

PubMed ID: 34716381 Exiting the NIEHS site

MeSH Terms: Adenocarcinoma/therapy*; Aged; Antineoplastic Agents/pharmacology*; Chemoradiotherapy/methods*; Drug Resistance, Neoplasm/drug effects; Esophageal Neoplasms/therapy*; Humans; Male; Middle Aged; Neoadjuvant Therapy*; Organoids/drug effects*; Pilot Projects; Precision Medicine; Prospective Studies

to Top